What is a Fecal Occult Blood Test (FOBT)?
A fecal occult blood test (FOBT) is a non-invasive screening test designed to detect hidden (occult) blood in stool that may originate from colorectal cancer or large polyps (≥1-2 cm). 1, 2
Test Categories and Mechanisms
FOBT encompasses two primary test types based on their detection methods 1, 2:
Guaiac-Based FOBT (gFOBT)
- Detection mechanism: Identifies blood through the pseudoperoxidase activity of heme or hemoglobin
- Most common stool blood test currently used for colorectal cancer (CRC) screening
- Only CRC screening test with evidence from prospective randomized controlled trials demonstrating mortality reduction of 15-33% over 8-13 years 1, 2
- Can be processed in physician's office or clinical laboratory
Fecal Immunochemical Test (FIT)
- Detection mechanism: Uses antibodies that react specifically to human globin
- Advantages over gFOBT: No dietary restrictions required, higher sensitivity and specificity
- Must be processed in a clinical laboratory
- Pooled sensitivity of 79% for CRC with 94% specificity 3
Proper Testing Protocol
For effective screening, FOBT requires annual testing with collection of 2-3 specimens from consecutive bowel movements 1, 2. This is critical because:
- Small adenomatous polyps typically don't bleed
- Bleeding from cancers or large polyps is intermittent
- Blood may not be detectable in a single stool sample
- Test sensitivity improves with each additional sample collected
Important Pre-Test Requirements for gFOBT
Before testing with sensitive guaiac-based tests, patients should avoid 1, 2:
- Medications: Aspirin, NSAIDs (unless low-dose aspirin for vascular disease), vitamin C, iron supplements
- Foods: Red meat, poultry, fish, certain raw vegetables
- Reason: These cause diet-test interactions increasing false-positive and false-negative (vitamin C specifically) results
Note: FIT does not require dietary restrictions 3
Clinical Application and Follow-Up
Any positive FOBT result mandates complete colonoscopy to examine the entire colon and rule out cancer or advanced neoplasia 1, 2. The test is designed as a screening tool for asymptomatic average-risk adults aged 50 years and older (recently updated to 45 years) 4.
Critical Limitations and Pitfalls
When NOT to Use FOBT
FOBT should NOT be used for 5, 6, 7:
- Symptomatic patients (e.g., those with overt GI bleeding, iron deficiency anemia)
- Single-sample testing during digital rectal examination in office settings (very poor sensitivity)
- Hospitalized patients for diagnostic purposes
- Diagnostic workup of gastrointestinal symptoms
The evidence is clear: FOBT has poor sensitivity (58%) for identifying causes of iron deficiency anemia, with 42% of patients having false-negative results 6. In symptomatic patients, FOBT often leads to inappropriate management, delayed endoscopy, and increased costs without clinical benefit 5.
Test Performance Reality
While gFOBT has proven mortality benefit in screening trials 8, 2, single-test sensitivity is relatively low (30-50% range) 8. Program sensitivity through repeated annual testing can detect up to 92% of cancers 8, emphasizing why one-time testing is inadequate.
For advanced adenomas (precancerous polyps), sensitivity is even lower at 27.1%, though it improves to 65.8% for invasive cancer 9. Sensitivity also varies by tumor location, being significantly lower for proximal colon lesions compared to distal colon (16.3% vs 30.7%) 9.
Screening Context
FOBT is one acceptable option among multiple colorectal cancer screening strategies 1, 2, 4. Tests that detect both adenomatous polyps and cancer (colonoscopy, flexible sigmoidoscopy, CT colonography) should be prioritized when resources are available and patients are willing, as colon cancer prevention should be the primary screening goal 2.
Patients choosing FOBT must understand that these tests are less likely to prevent cancer compared to invasive tests, must be repeated annually to be effective, and require colonoscopy if abnormal 2.